Human-centered Injury Thrivorship Pathway for Survivors of Physical Trauma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
The goal of this clinical trial is to pilot and evaluate a human-centered injury thrivorship pathway in injury survivors. The main question it aims to answer is:
• Is the pathway appropriate, acceptable, and feasible to meet the medical and social needs of injury survivors?
Injury survivors will be purposively sampled to enroll in the pathway and asked to participate in in-depth interviews and their use of pathway resources will be tracked.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patient ≥ 18 years old presenting with a physical injury to Zuckerberg San Francisco General Hospital
Admitted to the hospital ≥ 24 hours
Discharged from the hospital alive
San Francisco resident or unhoused in San Francisco
Disqualifiers
Patient < 18 years old
Deceased during index hospitalization
Unable to provide informed consent
Trial design
Design model
Single group
Treatments tested in this trial
Human-Centered Injury Thrivorship Pathway
Other interventionEnrollment in the human-centered injury thrivorship pathway.
Treatment groups
25 Participants
are divided into 1 treatment groupGroup A: Injury Thrivorship PathwayExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Early Implementation Outcomes - Acceptability, Appropriateness, Feasibility
Early implementation outcomes will be assessed via purposive sampling of pathway participants, their caregivers, and trauma care stakeholders for in-depth semi-structured interviews. "Acceptability is the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. Appropriateness is the perceived fit, relevance, or compatibility of the innovation or evidence based practice for a given practice setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue or problem. Feasibility is defined as the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting."
Time frame
8-12 weeks post-pathway enrollmentSecondary outcomes
1
Participant pathway resource utilization - type
Participant engagement with applicable pathway resources will be tracked by type of resource(s) accessed
Time frame
8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year2
Participant pathway resource utilization - frequency
Participant engagement with applicable pathway resources will be tracked by frequency of use of the resource(s)
Time frame
8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year3
Participant pathway resource utilization - duration
Participant engagement with applicable pathway resources will be tracked by duration of use of the resource(s)
Time frame
8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 year4
Participant pathway resource utilization - % utilized
Participant engagement with applicable pathway resources will be tracked by overall % of resources utilized out of resource(s) offered
Time frame
8-12 weeks post-pathway enrollment plus subsequent time points if continued resource engagement until study completion up to 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of California, San Francisco
Lead sponsor
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: